MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
210.65
+1.78
+0.85%
After Hours: 211.00 +0.35 +0.17% 18:41 08/13 EDT
OPEN
212.98
PREV CLOSE
208.87
HIGH
215.61
LOW
208.79
VOLUME
860.09K
TURNOVER
--
52 WEEK HIGH
219.72
52 WEEK LOW
127.71
MARKET CAP
31.12B
P/E (TTM)
37.30
1D
5D
1M
3M
1Y
5Y
1D
Biogen Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones · 5h ago
Biogen Price Target Announced at $300.00/Share by Wolfe Research
Dow Jones · 5h ago
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target
Benzinga · 5h ago
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE) and Biogen (BIIB)
TipRanks · 7h ago
Barclays Keeps Their Hold Rating on Biogen (BIIB)
TipRanks · 14h ago
Regeneron, Tenet leads top healthcare companies with highest earnings beats
Seeking Alpha · 1d ago
Biogen’s Long-Term Spinraza Study Wraps Up, Setting the Stage for Key SMA Data
TipRanks · 2d ago
Weekly Report: what happened at BIIB last week (0803-0807)?
Weekly Report · 3d ago
More
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.